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ABSTRACT 
 
Lower respiratory tract infections (LRTI`s) are the fifth leading cause of death due to infections being re-
sponsible for 2.74 million deaths worldwide. Antibiotics are used primarily to treat these infections. The 
aim of this research is to study the medication therapy management of patients with lower respiratory tract 
infections admitted in ESI hospital, Bangalore and to improve the quality of life of patients. It is a descriptive, 
observational, and interventional study. The data is collected through suitably designed forms and by direct 
interaction with the patients as well as their care takers. The study cohort consists of 40 patients, of that 
males were 24 (60%) and females were 16 (40%). Most of the infected cases were in the age group of 51 to 
60 years and minimum infected were of 11 to 20 years and 81 to 90 years. The symptoms like Hyperthermia 
(30%), Tachycardia and tachypnea (32.5%) were observed. High count of RBS, PPBS, FBS were seen among 
25%. Observations including leukocytopenia (7.5%), neutropenia (15%), lymphocytopenia (22.5%), leuko-
cytosis (22.5%), neutrophilia (27.5%), lymphocytosis (35%), eosinophilia (7.5%), monocytosis (2.5%), and 
all cases have increased ESR (100%). LRTI was among 13 (32.5%) patients and remaining were with com-
plications associated with LRTI. 40 (100%) patients received IV fluids along with Duolin, Budecort, Aug-
mentin, Cough syrup, and Deriphylline. Maximum drug interactions are seen in Pantoprazole + Deriphylline 
combination among 14 (35%). Process measures (type and frequency of drug therapy problems detected), 
economic measures (number of medications dispensed), and humanistic measures, (patient satisfaction 
with services) were the main outcomes in this process after providing MTM services. 
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INTRODUCTION 
Lower respiratory tract infection (LRTI) is a generic 
term for an acute infection of the trachea, airways, 
and lungs, which make up the respiratory system. 
LRTI`s include bronchitis, bronchiolitis, influenza, 
Tuberculosis, pneumonia. These acute lower infec-
tions are a leading cause of sickness and mortality 
both in children and adults worldwide. Every year 
about 5 million people die of acute respiratory infec-
tions.[1] According to the Global Burden of Disease 
2015 study (GBD 2015), chronic obstructive pulmo-
nary disease (COPD) and lower respiratory tract in-
fections represent the third and fourth most common 
causes of death respectively.[2] Among LRTI`s, pneu-
monia represents the most frequent cause of mortal-
ity, hospitalization and medical consultation. Several 
factors (age, underlying disease, and environment) 
influence mortality, morbidity, and microbial etiol-
ogy.[1] 
Bronchitis causes inflammation of the bronchial 
tubes. The inflammation leads to the swelling of the 
lining of these breathing tubes, narrowing the tubes 
and promoting secretion of inflammatory fluids. 
Bronchiolitis is a first time wheezing with a viral res-
piratory infection. It is a common respiratory illness 
in children less than 24 months with its peak inci-
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dence between 3 to 6 months of age. Influenza is com-
monly referred as the flu, is an infectious viral disease 
caused by RNA viruses of the family Orthomyxoviri-
dae (the influenza viruses) that affects birds and 
mammals. Tuberculosis is a second largest infectious 
disease caused by Mycobacterium tuberculosis that 
usually affects lungs although other organs may also 
be involved. Pneumonia is an inflammatory condition 
of the lung especially affecting the microscopic air 
sacs (alveoli), and the parenchyma of the lung. 
Infections are caused by tiny organisms known as 
bacteria or viruses, which are usually the most com-
mon cause. They are carried in tiny droplets and 
passed between people by coughing, sneezing and at 
times by indirect contact with surfaces. People who 
are infected usually produce antibodies to fight the 
virus. If re-infected, the antibodies help to fight the in-
fection with the same strain. Less frequently, these 
bacteria can go on to cause a LRTI. Symptoms of 
lower respiratory tract infections vary and depend on 
the severity of the infection. Less severe infections 
can have symptoms similar to the common cold, in-
cluding stuffed up or a runny nose, dry cough, low fe-
ver, mild sore throat, and headache.[3] In more severe 
infections, symptoms include a severe cough that 
may produce phlegm, fever, difficulty breathing, blue 
tint to the skin, rapid breathing, chest pain, and 
wheezing. Patients with LRTI and other comorbid 
conditions need excessive care among treatment be-
cause polypharmacy may lead to drug related prob-
lems. To overcome from these drug related problems, 
medication therapy management (MTM) process is 
undertaken with five different steps which provides 
interventions and improves patient's quality of life. 
Medication adherence, patient counselling and pa-
tient education are the important factors [4] among 
them. 
The aim of this research is to study the medication 
therapy management of patients with lower respira-
tory tract infections admitted in ESI hospital-Banga-
lore and to improve the quality of life of patients by 
addressing the issues of polypharmacy, preventable 
adverse events, medication adherence, and medica-
tion misuse. To improve outcomes by helping people 
to better understand their health conditions and the 
medications used to manage them and to develop a 
model frame work of MTM, designs to improve care, 
enhance communication among patients and provid-
ers, improve collaboration among providers, and op-
timize medication use that leads to improved patient 
outcomes. 
METHODOLOGY 
Study design and site: It is a descriptive, observa-
tional, and interventional study which was conducted 
in an ESI hospital (Indiranagar, Bangalore). LRTI pa-
tients willingly participated in this study, and all nec-
essary approvals from the institutional ethical com-
mittee at Gautham College of pharmacy, Bangalore 
were obtained before beginning the study. 
Study sample: 40 inpatients are diagnosed with LRTI 
and undergone medication therapy during the study 
period of six months from November 2019 to April 
2020 and were included in this study. 
Data collection: Suitably designed data collection 
forms were prepared to collect the details from the 
inpatients in ESI hospital. Case report forms of pa-
tients were collected from the concerned wards and 
laboratory data is collected from the labs and further 
required data is collected by the interaction among 
the doctors, nurses, and patients. Informed consent 
was taken from each patient, containing the neces-
sary information regarding the study. The data collec-
tion includes patient details like demographics, signs 
and symptoms, type of infectious disease and treat-
ment given to the patient. Discussions were done 
with respective physicians, guide, and nurses for 
elaboration of the study regarding concerned patient 
reports.  
Case report forms, laboratory reports like complete 
blood count, biochemistry reports and complete 
urine analysis and other required tests of the patient 
were analysed. Various parameters during hospitali-
zation were studied, and all required details like pa-
tient demographics, vitals, systemic examination, di-
agnosis, treatment (dose, date of drug started and 
stopped), drug interactions and adverse drug reac-
tions were monitored. The incidence of drug interac-
tions in patients is seen and they most often involve 
medications to treat comorbid conditions. Data col-
lected was analysed and compared with available 
studies. We contributed significantly by checking the 
treatment prescribed and detecting interactions, to 
reduce medication related problems and to optimize 
drug therapy for these patients.  
Statistical tools: The parameters monitored were 
entered in Microsoft excel 2016 and applied descrip-
tive studies for each parameter included in the pa-
tients. The incidence rate was calculated as the 
change in variable in patients (numerator) per the to-
tal number of patients in particular disease (denomi-
nator). The tables and graphs were drawn for each 
variable present in case sheets and also calculated 
percentages for each table. 
RESULTS 
Total number of the patients were 40, of whom 24 
(60%) were males and 16 (40%) were females (Table 
1 & Figure 1). Age wise distribution ranges from 0 to 
90 years. 3 (7.5%) patients were in the age group of 0 
to 10 years, 1(2.5%) patient was of 11 to 20 years, 3 
(5%) patients were in the age group of 21 to 30 years, 
3 (7.5%) patients were in the age group of 31 to 40 
years, 7 (17.5%) patients were in the age group of 41 
to 50 years, 16 (40%) patients were maximum in the 
age group of 51 to 60 years, 5 (12.5%) patients were 
in the age group of 61 to 70 years, 2 (5%) patients 
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were in the age group of 71 to 80 years. 1(2.5%) pa-
tient were in the age group of 81 to 90 years (Table 2 
& Figure 2). 
Table 1: Gender wise distribution in LRTI hospitalized 
patients 
Sl.no Gender 
Number of  
patients 
Percentage of  
patients (%) 
1 Males 24 60 
2 Females 16 40 
 
Figure 1: Gender wise distribution in LRTI hospitalized 
patients based on percentage 
Table 2: Age wise distribution in LRTI hospitalized pa-
tients 
Sl.no 
Age group 
in years 
Number of 
patients 
Percentage of 
patients (%) 
1 0 to 10 3 7.5 
2 11 to 20 1 2.5 
3 21 to 30 2 5 
4 31 to 40 3 7.5 
5 41 to 50 7 17.5 
6 51 to 60 16 40 
7 61 to 70 5 12.5 
8 71 to 80 2 5 
9 81 to 90 1 2.5 
 
Figure 2: Age wise distribution in LRTI hospitalized pa-
tients based on percentage 
Average duration of stay in hospital was 4 days in 
LRTI patients. On day 1 of hospitalization, 28 (70%) 
patients had normal body temperature (normal BT 
97.7 - 99.5 ᵒF), 12 (30%) patients had hyperthermia 
(>99.5 ᵒF). On day 2 of hospitalization, 34 (85%) pa-
tients had normal body temperature, 6 (15%) Pa-
tients had hyperthermia (<97.7ᵒF). All patients 
achieved a normal body temperature on days 3 and 4. 
None of the patients had hypothermia on hospitalized 
days and hyperthermia was not observed on days 3 
and 4 (Table 3 & Figure 3). 
 
Figure 3: Distribution based on change in body tem-
perature in LRTI hospitalized patients in percentage 
On day 1 of hospitalization, 37 (92.5%) patients had 
a normal pulse rate (PR) 60-100 bpm, 3 (7.5%) Pa-
tients had tachycardia (>100 bpm). On day 2 of hos-
pitalization, 39 (97.5%) patients had a normal PR, 1 
(1.75%) Patient had tachycardia. On third and fourth 
day of hospitalization, 40 (100%) patients had a nor-
mal PR and none of them had bradycardia (<60 bpm) 
on hospitalized days. Tachycardia was also nil on 
days 3 and 4 (Table 4 & Figure 4). 
 
Figure 4: Distribution based on change in pulse rate in 
LRTI hospitalized patients in percentage 
On day 1 of hospitalization, 37 (92.5%) patients had 
normal respiratory rate (RR 12-20 cpm) and 3 (7.5%) 
patients had tachypnea. On day 2 of hospitalization, 
27 (67.5 %) patients had normal RR and 13 (32.5%) 
patients had tachypnea (> 20 cpm). On day 3 of hos-
pitalization, 36 (90%) patients had normal RR and 4 
(10%) patients had tachypnea. On day 4 of hospitali-
zation, 39 (97.5%) patients had normal RR and 
1(2.5%) patient had tachypnea. None of the patients 
had Bradypnea (< 12 cpm) in hospitalized days (Ta-
ble 5 & Figure 5). 
In systemic examination, especially in cardiovascular 
system examination, 29 (72.5%) patients had S1S2 
positive, S1 is Lub (First heart sound) and S2 is Dub 
(Second heart sound). Unclear observation was in 11 
(27.5%) patients. In respiratory system examination,  
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Table 3: Distribution based on change in body temperature in LRTI hospitalized patients 
Patients having change in 
respiratory rate on 
Day 1 Day 2 Day 3 Day 4 
Sl.no Range 
In 
num-
ber 
In per-
centage 
(%) 
In 
num-
ber 
In percent-
age (%) 
In 
num-
ber 
In percent-
age (%) 
In 
num-
ber 
In percent-
age (%) 
1 
Normal  
(97.7ᵒF- 99.5 ᵒF) 
28 70 34 85 40 100 40 100 
2 
Hypothermia (< 
97.7ᵒF) 
0 0 0 0 0 0 0 0 
3 
Hyperthermia (>99.5 
ᵒF) 
12 30 6 15 0 0 0 0 
Table 4: Distribution based on change in pulse rate in LRTI hospitalized patients 
Patients having change in 
respiratory rate on 
Day 1 Day 2 Day 3 Day 4 
Sl.no Range 
In 
num-
ber 
In per-
centage 
(%) 
In 
num-
ber 
In per-
centage 
(%) 
In 
num-
ber 
In per-
centage 
(%) 
In 
num-
ber 
In per-
centage 
(%) 
1 
Normal (60-100 
Bpm) 
37 92.5 39 97.5 40 100 40 100 
2 
Bradycardia (< 60 
Bpm) 
0 0 0 0 0 0 0 0 
3 
Tachycardia (>100 
Bpm) 
3 7.5 1 2.5 0 0 0 0 
Table 5: Distribution based on change in respiratory rate in LRTI hospitalized patients 
Patients having change in 
respiratory rate on 
Day 1 Day 2 Day 3 Day 4 
Sl.no Range 
In 
num-
ber 
In per-
centage 
(%) 
In 
num-
ber 
In per-
centage 
(%) 
In 
num-
ber 
In per-
centage 
(%) 
In 
num-
ber 
In per-
centage 
(%) 
1 
Normal (12-20 
Cpm) 
37 92.5 27 67.5 36 90 39 97.5 
2 
Bradypnea (< 12 
Cpm) 
0 0 0 0 0 0 0 0 
3 
Tachypnea(> 20 
Cpm) 
3 7.5 13 32.5 4 10 1 10 
Table 6: Systemic examination of Cardiovascular, respiratory, and central nervous system in LRTI hospital-
ized patients 
Sl.no System 
S1S2+ Bilateral creps NAD NVBS WNL 
Unclear obser-
vation 
In 
num-
ber 
In per-
cent-
age 
(%) 
In 
num-
ber 
In per-
cent-
age 
(%) 
In 
num-
ber 
In per-
cent-
age 
(%) 
In 
num-
ber 
In per-
cent-
age 
(%) 
In 
num-
ber 
In per-
cent-
age 
(%) 
In 
num-
ber 
In per-
cent-
age 
(%) 
1 
Cardio-
vascular 
system 
29 72.5 nil nil nil nil nil nil nil nil 11 27.5 
2 
Respira-
tory sys-
tem 
nil nil 5 12.5 6 15 11 27.5 nil nil 18 45 
3 
Central 
Nervous 
system 
nil nil nil nil 3 7.5 nil nil 9 22.5 28 70 
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Figure 5: Distribution based on change in respiratory 
rate in LRTI hospitalized patients in percentage 
5 (12.5%) patients had bilateral crepts. No abnormal-
ities detected (NAD) in 6 (15%) patients and non-ve-
sicular breath sound (NVBS) was in 11 (27.5%) pa-
tients and unclear observation was among 18 (45 %) 
patients. In central nervous system, 3 (7.5%) patients 
had NAD, 9 (22.5%) patients were within normal lim-
its (WNL) and 28 (70%) patients had unclear obser-
vation (Table 6 & Figure 6). 20 (50%) patients had 
soft abdomen and 20 (50%) patients had unclear ob-
servation in abdomen examination. Congested throat 
was present in 5 (12.5 %) patients and it was absent 
in 35 (87.5%) patients (Table 7 & Figure 7). 
 
Figure 6: Systemic examination of Cardiovascular, res-
piratory, and central nervous system in LRTI hospital-
ized patients based on percentage 
 
Figure 7: Systemic examinations like presence of soft 
abdomen and congested throat in LRTI hospitalized 
patients based on percentage 
29 (72.5%) patients had normal RBS levels (80-160 
mg/dl), 1 (1.75%) patient had low RBS levels and 10 
(25%) patients had high RBS (>160 mg/dl) levels. 30 
(75%) patients had normal range of PPBS (70-140 
mg/dl) and FBS (70-110 mg/dl), 10 (25%) patients 
had high PPBS (>140 mg/dl) and RBS levels (>160 
mg/dl). None of the patients had low sugar levels of 
PPBS & FBS in the blood (Table 8 & Figure 8). 
 
Figure 8: Blood sugar levels in LRTI hospitalized pa-
tients based on percentage 
18 (45%) patients had normal range (5,000 - 10,000 
cells/cumm), 3 (7.5%) patients had low and 9 
(22.5%) patients had high WBCs (>10,000 
cells/cumm). In males, 22 (91.66%) patients had nor-
mal levels, 2 (8.33%) patients had low haemoglobin 
levels. In females, 14 (87.5%) patients had normal 
levels, 2 (12.5%) patients had high haemoglobin lev-
els. 38 (95%) patients had normal (1.5 - 4.0 
Lakhs/cumm) and 2 (5%) patients had high platelet 
count (>4.0 Lakhs/cumm). 23 (57.5%) patients had 
normal level (50 - 75%), 6 (15%) patients had low 
and 11 (27.5%) patients had high neutrophils (>75 
%). 17 (42.5%) patients had normal level (25 – 40%), 
9 (22.5%) patients had low and 14 (35%) patients 
had high Lymphocytes (>40%). 37 (92.5%) patients 
had normal range (1 – 6%) and 3 (7.5%) patients high 
Eosinophils (>6%). 39 (97.5%) patients had normal 
range (2 – 10 %) and 1 (2.5%) patient had high mon-
ocytes (>10%). All the study population had high ESR. 
Most of the patients had normal range of parameters 
like monocytes, platelets, and haemoglobin besides 
they also had low count of neutrophils and lympho-
cytes. High levels of ESR is present in all patients (Ta-
ble 9 & Figure 9). 
 
Figure 9: Haematology reports in LRTI hospitalized pa-
tients based on percentage 
13 (32.5%) patients had lower respiratory tract in-
fection (LRTI). 6 (15%) patients had LRTI with diabe-
tes mellitus. 4 (10%) patients had LRTI with diabetes 
mellitus and hypertension. 3 (7.5%) patients had  
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Table 7: Systemic examinations like presence of soft abdomen and congested throat in LRTI hospitalized pa-
tients 
Sl.no Parameters 
Present Absent Unclear observation 
Number Percentage (%) Number Percentage (%) Number Percentage (%) 
1 Soft abdomen 20 50 nil nil 20 50 
2 Congested throat 5 12.5 35 87.5 nil nil 
Table 8: Blood sugar levels in LRTI hospitalized patients 
Sl.no Parameters 
Normal range Low High 
Number Percentage (%) Number Percentage (%) Number Percentage (%) 
1 RBS 29 72.5 1 2.5 10 25 
2 PPBS 30 75 0 0 10 25 
3 FBS 30 75 0 0 10 25 
Table 9: Haematology reports in LRTI hospitalized patients 
Sl.no 
Parameters 
 
Normal range Less than normal range More than normal range 
Number 
Percentage 
(%) 
Number 
Percentage 
(%) 
Number 
Percentage 
(%) 
1 WBC 18 45 3 7.5 9 22.5 
2 Hb in males 22 91.66 2 8.33 0 0 
3 Hb in females 14 87.5 2 12.5 0 0 
4 Platelet count 38 95 0 0 2 5 
5 Neutrophils 23 57.5 6 15 11 27.5 
6 Lymphocytes 17 42.5 9 22.5 14 35 
7 Eosinophils 37 92.5 0 0 3 7.5 
8 Monocytes 39 97.5 0 0 1 2.5 
9 ESR in males 0 0 0 0 24 100 
10 ESR in females 0 0 0 0 16 100 
Table 10: Complications associated with LRTI 
Sl.no Disease condition 
Number of pa-
tients 
Percentage of patients 
(%) 
1 Lower respiratory tract infection 13 32.5 
2 Lower respiratory tract infection with diabetes mellitus 6 15 
3 
Lower respiratory tract infection with diabetes mellitus and hy-
pertension 
4 10 
4 Lower respiratory tract infection with hypertension 3 7.5 
5 Lower respiratory tract infection with bronchial asthma 3 7.5 
6 
Lower respiratory tract infection with chronic obstructive pulmo-
nary disorder 
9 22.5 
7 Lower respiratory tract infection with viral fever 2 5 
Table 11: Drugs used in LRTI hospitalized patients 
Sl.no Drugs Number of patients Percentage of patients % 
1 IV Fluids 40 100 
2 Deriphylline 37 92.5 
3 Monocef 31 77.5 
4 Pantodac 17 42.5 
5 Duolin 40 100 
6 Budecort 40 100 
7 Augmentin 40 100 
8 Montek LC 37 92.5 
9 Cough syrup 40 100 
10 Humolog 10 25 
11 Metformin 10 25 
12 Lasix 7 17.5 
13 Dytor 7 17.5 
14 Methyl prednisalone 3 7.5 
15 Polytaz 9 22.5 
16 paracetamol 28 70 
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LRTI with hypertension and LRTI with bronchial 
asthma. 9 (22.5%) patients had LRTI with Chronic ob-
structive pulmonary disorder. 2 (5%) patients had 
LRTI with viral fever. Most of the infected cases have 
LRTI infections only i.e. in 13 (32.5%) patients and 
least infected cases have LRTI with viral fever i.e. in 2 
(5%) patients (Table 10 & Figure 10). 
 
Figure 10: Complications associated with LRTI hospi-
talized patients based on Percentage 
 
Figure 11: Drugs used in LRTI hospitalized patients 
based on percentage 
The drugs used in the therapy of LRTI hospitalized 
patients are 40 (100%) patients received IV fluids, 
Duolin, Budecort, Augmentin, Cough syrup and De-
riphylline. 37 (92.5%) patients received Deriphylline 
and Montek LC. 31 (77.5%) patients received Mo-
nocef, 17 (42.5%) patients received Pantoprazole, 10 
(25%) patients received Humolog and metformin, 7 
(17.5 %) patients received Lasix and dytor, 3 ( 7.5%) 
patients received Methyl prednisalone, 9 (22.5%) pa-
tients received Polytaz and 28 (70%) patients re-
ceived paracetamol (Table 11 & Figure 11). 
Table 12: Drug interactions 
Sl.no Interacting 
drugs 
Number of 
patients 
Percentage of 
patients (%) 
1 Pantoprazole + 
Deriphylline 
14 35 
2 Torsemide + 
metformin 
4 10 
3 Methyl prednisa-
lone +Deriphyl-
line 
3 7.5 
Pantoprazole + Deriphylline had drug interactions 
among 14 (35%) patients. Torsemide + Metformin 
had drug interactions among 4 (10%) patients. Me-
thyl prednisalone + Deriphylline had drug interac-
tions among 3 (7.5%) patients (Table 12 & Figure 
12). 
 
Figure 12: Drug interactions in LRTI hospitalized pa-
tients 
DISCUSSION 
Lower respiratory tract infections (LRTIs) are the 
commonest health problem demanding frequent con-
sultation and hospitalization and are more prevalent 
in males than females. The reasons behind high risk 
in males of LRTI is attributable to tobacco, smoking, 
alcohol consumption etc. producing decreased local 
immunity in the respiratory tract due to defective 
mucociliary clearance, mucous plugging, airway col-
lapse, respiratory muscle fatigue and the conse-
quence of medication used [5]. Females enrolled in the 
study comprised largely of housewives, who being 
less mobile experienced, less exposure to respiratory 
risk factors. Almost patients admitted with the reason 
of fever, cough, tiredness, weakness, breathlessness, 
body ache, difficulty in breathing in our study. The 
main symptoms were cough, snuffle, fever, chilly, 
chest distress and pain and elevation of blood sugar 
levels in diabetic patients. Similar symptoms were 
found in a study conducted by Shah BA et al [6]. 
Almost 33 (82.5%) patients had normal blood pres-
sure and 7 (17.5%) patients had high blood pressure. 
This indicates 17.5% of study population had hyper-
tension and vitals will vary on the basis of other dis-
ease conditions. In systemic examination of patients, 
positive S1S2 was seen among 29 (72.5%) patients, bi-
lateral crepts and congested throat was observed 
among 5 (12.5%) patients and was less common. Soft 
abdomen was noted among 20 (50%) patients. Bilat-
eral crepts are due to inflammation of the bronchial 
tubes, pulmonary edema etc. 9 (22.5%) patients had 
hypoxia. 
ESR had higher diagnostic odds ratios than any of the 
symptoms and signs. Leukocyte count was remarka-
ble in patients hospitalized for COPD exacerbations 
with purulent sputum. [7] Patients with diabetes melli-
tus (DM) are likely to develop many types of infec-
tions, which affect the transport of glucose into tis-
sues. Diabetes increases the susceptibility to different 
kinds of respiratory infections and is often identified 
as an independent risk factor for developing lower 
respiratory tract infections.[8] 
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Antibiotic prescribing rates were high in acute bron-
chitis.[9] Antimicrobial therapy is a principal manage-
ment component for these diseases. Montelukast is a 
potent, specific, oral cysteinyl leukotriene 1 (cysLT1) 
receptor antagonist which improves bronchial 
asthma symptoms and reduces inhaled corticoster-
oids requirement and provides overview of evidence 
for the use of montelukast in patients with bronchial 
asthma and exercise induced asthma sleep disorder, 
respiratory syncytial virus (RSV), bronchiolitis and 
cystic fibrosis.[10] Mortality rate was nil in our study.  
Antibiotic resistance is a major public-health prob-
lem, in particular since resistance of microorganisms 
increases with the consumption of antibiotics.[11, 12] 
The majority of antibiotics are prescribed in primary 
care, mainly for the treatment of acute respiratory 
tract infections.[13] Oxygen supplementation is often 
recommended for people with severe lower respira-
tory tract infections.[14,15] Oxygen can be provided in 
a non-invasive manner using nasal prongs, face 
masks, a head box or hood, a nasal catheter, or a na-
sopharyngeal catheter. For children younger than 15 
years old, nasopharyngeal catheters or nasal prongs 
are recommended over a face mask or head box. A 
Cochrane review in 2014 presented a summary to 
identify children complaining of severe LRTI. How-
ever, further research is required to determine the ef-
fectiveness of supplemental oxygen and the best de-
livery method. 
Here we intervened to address medication related 
problems when necessary. A suitable intervention 
form was designed for clinical pharmacist interven-
tion. After completion of medication therapy review 
(MTR), personal medication record (PMR) and medi-
cation action plan (MAP), the problems related to 
drugs are noted by clinical pharmacist. We provided 
a response to a drug related problem. We performed 
intervention to improve the safety and efficacy of 
medications in collaboration with the physicians. We 
also provided counseling to the patients for their dis-
ease conditions. We informed them regarding drug 
interactions and their effect on patients with LRTI 
diseases. In some patients with multiple complica-
tions requiring referral to another physician or phar-
macist for disease management. we educated them 
about how to manage chronic diseases like diabetes 
and hypertension. 
We provided MTM services to all the study popula-
tion throughout the 6 months period and identified 
drug-related problems and relayed the recommenda-
tions to their physician and physicians accepted our 
recommendations. Patients reported feeling better 
about their medications after receiving MTM ser-
vices. Process measures (type and frequency of drug 
therapy problems detected, and services performed), 
economic measures (number of medications dis-
pensed), and humanistic measures (patient satisfac-
tion with services) were the main outcomes in this 
process. We provided the educational services like 
medication use, disease management, adherence, and 
self-care. Nearly all patients received some form of 
medication adherence or disease education associ-
ated with problem detection and resolution. MTM 
may reduce outpatient visits to address side effects. 
This process is broadly applicable to a range of chron-
ically ill adult patient populations. A majority of inter-
ventions were directed at populations with multiple 
and chronic conditions such as diabetes and hyper-
tension. Specifically, we found evidence that MTM re-
sults in improvement when compared with usual 
care for some measures of medication adherence. 
CONCLUSION 
LRTI varies according to serotype, age, socioeco-
nomic status, and environmental factors. Classical 
cases have clinical symptoms of fever, cough, tired-
ness, weakness, breathlessness, body aches, and dif-
ficulty in breathing. Antimicrobial therapy is a princi-
pal management component for these diseases. It is 
often difficult to diagnose and differentiate atypical 
infections from these infections. Clinical findings and 
radiological imaging may help to identify and treat 
atypical infections. Prescribing the appropriate anti-
biotic is important to obtain the optimal patient re-
sponse. When more than one drug has been sug-
gested, preference should be given to the drug with 
the fewest adverse effects and lowest cost, and par-
ticularly the one patient is likely to take. 
MTM services provide an opportunity for clinical 
pharmacists to develop direct patient care services, 
patient care activities including patient counseling, 
disease management, and all currently provided 
pharmacy services. In addition to Medicare-eligible 
patients, MTM services are appropriate for anyone 
with medication-related needs. MTM is offered as an 
all-encompassing model that incorporates the philos-
ophy of pharmaceutical care, techniques of patient 
counseling, and disease management in an environ-
ment that facilitates the direct collaboration of pa-
tients, pharmacists, and other health professionals. 
Clinical pharmacists are strategically positioned to 
provide MTM services and effectively communicate 
with providers to improve quality of care for patients. 
Thus, MTM has been helping countless number of pa-
tients to better understand their health conditions 
and the medications used to manage them. MTM has 
resulted in reductions in physician visits, emergency 
department visits, hospital days. 
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